Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Grows By 7.0%

Arvinas, Inc. (NASDAQ:ARVN) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 10,440,000 shares, an increase of 7.0% from the January 15th total of 9,760,000 shares. Based on an average daily trading volume, of 885,500 shares, the days-to-cover ratio is currently 11.8 days.

Institutional Investors Weigh In On Arvinas

Institutional investors and hedge funds have recently bought and sold shares of the business. nVerses Capital LLC acquired a new stake in Arvinas in the 3rd quarter valued at about $39,000. KBC Group NV lifted its holdings in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Arvinas by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after buying an additional 440 shares in the last quarter. Quantbot Technologies LP lifted its stake in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after buying an additional 2,601 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Arvinas by 37.0% in the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after buying an additional 1,798 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Stock Up 3.6 %

Shares of ARVN opened at $18.31 on Monday. Arvinas has a 52-week low of $16.61 and a 52-week high of $53.08. The firm has a market capitalization of $1.26 billion, a PE ratio of -3.92 and a beta of 1.88. The firm has a 50-day moving average price of $18.88 and a 200 day moving average price of $23.16.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same quarter last year, the company earned ($2.53) earnings per share. On average, equities analysts expect that Arvinas will post -3.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Barclays dropped their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. BTIG Research assumed coverage on Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective for the company. Stephens initiated coverage on Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating and set a $57.00 price target on shares of Arvinas in a research report on Wednesday, February 12th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Arvinas currently has a consensus rating of “Buy” and a consensus price target of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.